San Diego-based Neuropore Therapies Inc., a biotechnology firm, has entered into a collaboration agreement with Belgium-based UCB S.A. to develop and commercialize products that may slow the progression of Parkinson’s disease and related disorders.

Neuropore will receive an initial upfront payment of $20 million, along with the potential to earn $460 million in milestone payments, in addition to royalties on net sales.

Neuropore’s product is called NPT200-11, which is expected to enter clinical development in 2015.